Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Dryden

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Infectious Diseases|February 19, 2015
Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?Matthew S Dryden
The Journal of Antimicrobial Chemotherapy|April 28, 2011
Linezolid pharmacokinetics and pharmacodynamics in clinical treatmentMatthew S Dryden
The Journal of Antimicrobial Chemotherapy|September 30, 2010
Complicated skin and soft tissue infectionMatthew S Dryden
Current Opinion in Infectious Diseases|February 5, 2014
Developments in skin and soft tissue infectionMatthew S Dryden
International Journal of Antimicrobial Agents|June 30, 2009
Skin and soft tissue infection: microbiology and epidemiologyMatthew S Dryden
Current Opinion in Infectious Diseases|February 8, 2014
Novel antibiotic treatment for skin and soft tissue infectionMatthew S Dryden
The Journal of Antimicrobial Chemotherapy|September 5, 2009
Antibiotic stewardship--more education and regulation not more availability?Matthew S Dryden, Jonathan Cooke, Peter Davey
BMJ (Clinical Research Ed.)|November 21, 2012
European Antibiotic Awareness Day and access to antibioticsNicholas M Brown, Laura J V Piddock, Matthew S Dryden, et al.
Practical Neurology|October 5, 2018
Lyme disease: diagnosis and managementAmy L Ross Russell, Matthew S Dryden, Ashwin A Pinto, et al.
American Journal of Surgery|March 16, 2010
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureusKamal M F Itani, Matthew S Dryden, Helen Bhattacharyya, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Infectious Diseases|February 19, 2015
Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?Matthew S Dryden
The Journal of Antimicrobial Chemotherapy|April 28, 2011
Linezolid pharmacokinetics and pharmacodynamics in clinical treatmentMatthew S Dryden
The Journal of Antimicrobial Chemotherapy|September 30, 2010
Complicated skin and soft tissue infectionMatthew S Dryden
Current Opinion in Infectious Diseases|February 5, 2014
Developments in skin and soft tissue infectionMatthew S Dryden
International Journal of Antimicrobial Agents|June 30, 2009
Skin and soft tissue infection: microbiology and epidemiologyMatthew S Dryden
Current Opinion in Infectious Diseases|February 8, 2014
Novel antibiotic treatment for skin and soft tissue infectionMatthew S Dryden
The Journal of Antimicrobial Chemotherapy|September 5, 2009
Antibiotic stewardship--more education and regulation not more availability?Matthew S Dryden, Jonathan Cooke, Peter Davey
BMJ (Clinical Research Ed.)|November 21, 2012
European Antibiotic Awareness Day and access to antibioticsNicholas M Brown, Laura J V Piddock, Matthew S Dryden, et al.
Practical Neurology|October 5, 2018
Lyme disease: diagnosis and managementAmy L Ross Russell, Matthew S Dryden, Ashwin A Pinto, et al.
American Journal of Surgery|March 16, 2010
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureusKamal M F Itani, Matthew S Dryden, Helen Bhattacharyya, et al.
Pageof 2